Tempus AI, Inc. (TEM)
NASDAQ: TEM · Real-Time Price · USD
51.44
-4.07 (-7.33%)
At close: Apr 23, 2026, 4:00 PM EDT
51.95
+0.51 (0.99%)
Pre-market: Apr 24, 2026, 5:21 AM EDT
Tempus AI Revenue
In the year 2025, Tempus AI had annual revenue of $1.27B with 83.41% growth. Tempus AI had revenue of $367.21M in the quarter ending December 31, 2025, with 82.98% growth.
Revenue (ttm)
$1.27B
Revenue Growth
+83.41%
P/S Ratio
7.25
Revenue / Employee
$334,681
Employees
3,800
Market Cap
9.22B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.27B | 578.39M | 83.41% |
| Dec 31, 2024 | 693.40M | 161.58M | 30.38% |
| Dec 31, 2023 | 531.82M | 211.15M | 65.85% |
| Dec 31, 2022 | 320.67M | 62.82M | 24.36% |
| Dec 31, 2021 | 257.85M | 69.85M | 37.15% |
| Dec 31, 2020 | 188.00M | 125.95M | 202.95% |
| Dec 31, 2019 | 62.06M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BrightSpring Health Services | 12.91B |
| Veeva Systems | 3.20B |
| Teladoc Health | 2.53B |
| Privia Health Group | 2.12B |
| HealthEquity | 1.31B |
| Omnicell | 1.18B |
| Waystar Holding | 1.10B |
| 10x Genomics | 642.82M |
TEM News
- 20 hours ago - Tempus and USC Announce Strategic Collaboration to Accelerate AI-Driven Precision Medicine - Business Wire
- 2 days ago - Tempus to Report First Quarter 2026 Financial Results on May 5 - Business Wire
- 8 days ago - Tempus and Predicta Biosciences Announce Collaboration to Expand Life Sciences Access to Ultrasensitive Whole-Genome Sequencing Assay for Hematologic Malignancies and MRD Monitoring - Business Wire
- 9 days ago - Tempus AI Stock Jumps As Data Presentations Fuel Fresh AI Oncology Buzz - Benzinga
- 9 days ago - Tempus Announces 31 Abstracts for Presentation at the American Association for Cancer Research Annual Meeting 2026 - Business Wire
- 10 days ago - Tempus Launches Automated “Active Follow-Up” Service to Support Guideline-Concordant Care - Business Wire
- 14 days ago - Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE - Business Wire
- 15 days ago - Tempus to Present at the 25th Annual Needham Virtual Healthcare Conference - Business Wire